Trial Profile
The Safety and Efficacy of 68Ga-HBED-CC-PSMA PET/CT in Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Diagnostic use
- 22 Nov 2023 Status changed from recruiting to completed.
- 20 Sep 2021 Planned End Date changed from 1 Jul 2024 to 1 Jul 2026.
- 20 Sep 2021 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.